Cork University Hospital
Cork, T12 DC4A, Ireland
NCT Number: NCT02371694
Background: Based on international evidence, current management of people with T1DM on intensive insulin therapy (IIT) use algorithms based on the meal carbohydrate content (MCC) to calculate the prandial insulin dose. Typically, these calculations do not take into account the protein or fat content of the meal. There is a lack of clinical advice for optimal management of high protein/fat meals due to a paucity of evidence regarding the impact of protein/fat on glycaemic control.
Objective: To determine the mean glucose excursion from fasting (measured by continuous glucose monitoring, CGMS) at each 30 minute interval over the 8 hour postprandial period for each test condition. Protein effects will be looked at in a separate parallel study in Australia.
Hypothesis: The fat content of a meal will cause a dose-response change in the postprandial glucose concentration in children with T1DM.
Research Design and Methods: Randomised cross-over study involving thirty patients. Inclusion criteria: T1DM >1 year, aged 8-18 years, with HbA1c <8% and BMI <91st centile, on intensive insulin therapy. Participants will be given a test meal on 6 consecutive nights in random order; 4 test meals varying in fat content, and one 20g carbohydrate test meal with zero fat given as control meal. A CGMS will be used to assess glucose responses at 5 minute intervals for 8 hours after test meal consumption. The relationship between the fat loads in the test meals and the mean change in postprandial glucose concentration will be analysed and described.
Conclusions: This study will determine whether fat causes dose dependent response in glucose concentrations leading to refining the guidelines and possible adjustment of insulin doses for the fat content of a meal.
Looking for future studies?
Notify Me8 year–18 year
All sexes
Interventional
Not applicable
Cork, T12 DC4A, Ireland
Objective 1 To define the impact of varying quantities (dose) of fat on the post-prandial glucose concentrations i.e. determine the relationship between the fat load in the test meals and the mean change in postprandial glucose concentrations.
Objective 2 To compare the impact of the varying fat quantities in the test meals each with a control carbohydrate snack (20g) without extra insulin.
To define the impact of lipid on the post-prandial glucose concentration, participants will consume a standardised meal at 18:00hours and receive a standard insulin bolus by injection or pump (using standard wave bolus if on insulin pump) based on the meal carbohydrate content. At 22:00 hours the participants will consume a lipid test meal dose (varying fat content of 2.5, 12.5, 25, 37.5, 50g) or carbohydrate snack 20g. The calculations of the fat doses have been based on the Pankowska algorithm [3] which recommends additional insulin for every 100 kcal fat or protein. There will be randomised order of test meals.
Test meals will be formulated to be palatable, consumed within 5 minutes and to contain negligible carbohydrate, protein and fibre. A dietician will design the test meals in conjunction with the co-investigator in detail to ensure ease of formulation and practical administration.
The lipid dose in test meals will be tested for acceptability and palatability to ensure adherence to protocol. The order of the test meal types/carbohydrate snacks will be random (computer generated randomisation). The comparator 20g carbohydrate snack has been included to assess the participant's typical glucose response to 20g of carbohydrate. No insulin will be given for the lipid or carbohydrate snacks. Participants will fast until breakfast.
The primary outcome of interest will be the Area Under the Curve (AUC) of glucose concentrations during the post prandial 8 hours. Linear regressions, within a generalised linear mixed model framework, will be used to test for a dose response in AUCs with increasing size of fat means.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
-
The intervention is a drink taken 4 hours after the evening meal insulin injection, or 10PM, whichever is later. All drinks are 116-120g in weight and similar volume.
All drinks are served in a double blind fashion, apart from the 20g carbohydrate which is visibly different from other drinks in colour, texture and flavour.
Time frame: During the 8 hours post drink
The mean glucose excursion from fasting (measured by CGMS) at each 30 minute interval over the 8 hour postprandial period for each test condition
Time frame: During the 24h post drink
Maximal change in glucose concentration (mMol)
Time frame: During the 8 hours post drink
Duration to reach maximal change in glucose concentration (minutes)
Time frame: During the 8 hours post drink
Duration to reach basal glucose concentration (minutes)
Time frame: During the 24h post drink
Duration spent in target glucose concentration (Minutes)
Time frame: During the 24 hours post drink
Number of hypoglycaemic events
Cork University Hospital
Other
What is the Dose Response of Varying Meal Content of Fat on Postprandial Glycaemia in Children With Type 1 Diabetes Mellitus?
Acronym: REQINSOIL
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06238778
Autoimmune Diseases, Diabetes Mellitus
Huntington Beach, California, United States
View Trial DetailsNCT06236256
Autoimmune Diseases, Diabetes Mellitus
Ramat Gan, Israel
View Trial DetailsNCT07711275
Autoimmune Diseases, Diabetes Mellitus
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT03938324
Anemia, Anemia, Hemolytic
Durham, North Carolina, United States
View Trial Details